新冠疫苗研发波折:Vaxart 获转机,行业仍陷困境

生物制品圈
29 Apr

近日,疫苗研发领域动态频出,Vaxart 公司迎来好消息,其新冠疫苗研究的暂停令被解除,研发进程得以重启。然而,整个新冠疫苗研发行业依旧面临诸多挑战,GeoVax 和诺瓦瓦克斯(Novavax)等公司深陷困境,并且,疫苗行业还受到来自卫生部门的质疑,未来发展充满不确定性。Vaxart 疫苗研究解冻,重启研发进程4 月 29 日,Vaxart 公司在向美国证券交易委员会(SEC)提交的文件中宣布,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10